Coriolan Lebreton
No ORCID on file
· 1 paper in corpus
review
2023
PURPOSE OF REVIEW: In spite of their rarity when considered individually, the sum of all rare ovarian tumours (ROT) represent almost half of all ovarian malignancies. As such, their appropriate inclusion within dedicated clinical trials is …